Magenta Therapeutics (MGTA) versus Its Peers Head to Head Analysis

Magenta Therapeutics (NASDAQ: MGTA) is one of 548 public companies in the “Pharmaceutical preparations” industry, but how does it weigh in compared to its competitors? We will compare Magenta Therapeutics to similar businesses based on the strength of its risk, dividends, profitability, analyst recommendations, earnings, valuation and institutional ownership.

Valuation & Earnings

This table compares Magenta Therapeutics and its competitors top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Magenta Therapeutics N/A -$57.51 million -4.80
Magenta Therapeutics Competitors $2.15 billion $228.73 million -3.52

Magenta Therapeutics’ competitors have higher revenue and earnings than Magenta Therapeutics. Magenta Therapeutics is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.

Analyst Recommendations

This is a breakdown of current ratings and target prices for Magenta Therapeutics and its competitors, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Magenta Therapeutics 0 1 4 0 2.80
Magenta Therapeutics Competitors 4546 13020 27669 994 2.54

Magenta Therapeutics presently has a consensus price target of $18.67, suggesting a potential upside of 24.36%. As a group, “Pharmaceutical preparations” companies have a potential upside of 58.60%. Given Magenta Therapeutics’ competitors higher possible upside, analysts plainly believe Magenta Therapeutics has less favorable growth aspects than its competitors.

Institutional & Insider Ownership

55.8% of Magenta Therapeutics shares are held by institutional investors. Comparatively, 46.3% of shares of all “Pharmaceutical preparations” companies are held by institutional investors. 14.9% of shares of all “Pharmaceutical preparations” companies are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Profitability

This table compares Magenta Therapeutics and its competitors’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Magenta Therapeutics N/A N/A N/A
Magenta Therapeutics Competitors -1,760.46% -120.17% -28.09%

About Magenta Therapeutics

Magenta Therapeutics, Inc., a clinical-stage biotechnology company, develops novel medicines to extend the curative power of stem cell transplant, gene therapy, genome editing, and cell therapy to patients. It is developing C100, C200, and C300 targeted antibody-drug conjugates for transplant conditioning; MGTA-145, a novel stem cell mobilization product candidate to control stem cell mobilization; MGTA-456, an allogeneic stem cell therapy to control stem cell growth; E478, a small molecule aryl hydrocarbon receptor antagonist for the expansion of gene-modified stem cells; and G100, an antibody-drug conjugate program to prevent acute graft and host diseases. The company was formerly known as HSCTCo Therapeutics, Inc. and changed its name to Magenta Therapeutics, Inc. in February 2016. Magenta Therapeutics, Inc. was founded in 2015 and is headquartered in Cambridge, Massachusetts.

Receive News & Ratings for Magenta Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Magenta Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.